- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Year of 2018
The Center for Biosimilars® recaps the top news of 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the most-read biosimilars articles for the year of 2018.
Number 5: In July, the FDA released its Biosimilar Action Plan.
Number 4: In September, the State of California sued AbbVie for allegedly using kickbacks and nurse ambassadors to boost adalimumab sales.
Number 3: In June, the FDA approved the first pegfilgrastim biosimilar, Fulphila.
Number 2: In April, the United Kingdom’s National Health Service prepared for the arrival of biosimilar adalimumab.
Number 1: In June, the FDA rejected Amgen’s trastuzumab biosimilar, ABP 980.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
